---
title: "Takeda President, R&D Andrew Plump sells 116,191 ADS for $2.15 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297977753.md"
description: "Takeda President of R&D Andrew Plump sold 116,191 American Depositary Shares (ADS) on September 2 for approximately $2.15 million at a price of $18.49 per share. Following the transaction, his holdings via trust decreased to 145,465 ADS, while his directly held position remained at 766,569 ADS."
datetime: "2026-09-04T01:49:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297977753.md)
  - [en](https://longbridge.com/en/news/297977753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297977753.md)
generator: "portal-rs"
---

# Takeda President, R&D Andrew Plump sells 116,191 ADS for $2.15 million

-   Takeda President, R&D Andrew Stewart Plump disclosed the sale of 116,191 American Depositary Shares on Sept. 2. \* Shares sold at USD 18.49 each; holdings via trust fell to 145,465 ADS. \* Directly held position remained 766,569 ADS following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001395064-26-000335), on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda's Entyvio disease-clearance strategy cuts ulcerative colitis complication risk nearly 70% in trial](https://longbridge.com/en/news/302266907.md)
- [Takeda says IgGNITE Phase 2/3 trial shows TAK-881 matches HyQvia pharmacokinetics in PID patients 16+](https://longbridge.com/en/news/301838986.md)
- [Takeda Chief Transformation Officer Lauren Rusckowski Duprey sells 34,535 shares for $640,278.9](https://longbridge.com/en/news/299110829.md)
- [Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems | TAK Stock News](https://longbridge.com/en/news/299399264.md)
- [Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1](https://longbridge.com/en/news/296890461.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**